We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

Shortages of funds, equipment and infrastructure hamper health-related research and development in developing countries. As a result, middle- and low-income countries account for just four per cent of the US$105.9 billion spent each year on global health research.

In this article, Fiona Fleck reveals that despite the challenges, many developing countries have devised creative solutions for meeting public health needs. Brazil, Indonesia and South Africa have built up expertise in making generic copies of drugs developed by Western companies, while Cuba and Croatia have produced new drugs. India has done both.

Now, many developing countries are exploring their own traditional medicine and indigenous plants for new ways of tackling disease, while teaming up with pharmaceutical giants to forge public-private partnerships and supply their local research and development centres with staff.

Link to article in Bulletin of the World Health Organization

Related topics